

# Martin Hutchings

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9035372/publications.pdf>

Version: 2024-02-01

161  
papers

9,616  
citations

70961

41  
h-index

38300

95  
g-index

164  
all docs

164  
docs citations

164  
times ranked

6108  
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3048-3058.	0.8	1,269
2	Early Interim 2-[ <sup>18</sup> F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 3746-3752.	0.8	799
3	FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. <i>Blood</i> , 2006, 107, 52-59.	0.6	694
4	Early Positron Emission Tomography Responseâ€“Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1786-1794.	0.8	397
5	FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. <i>Annals of Oncology</i> , 2005, 16, 1514-1523.	0.6	359
6	Omitting Radiotherapy in Early Positron Emission Tomographyâ€“Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1188-1194.	0.8	349
7	Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. <i>Annals of Oncology</i> , 2005, 16, 1160-1168.	0.6	300
8	International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers. <i>Journal of Nuclear Medicine</i> , 2013, 54, 683-690.	2.8	267
9	Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, iii70-iii75.	0.6	257
10	Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomographyâ€“Staged Treatment-Naive Patients With Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 4508-4514.	0.8	252
11	International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). <i>Annals of Oncology</i> , 2017, 28, 1436-1447.	0.6	249
12	Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv19-iv29.	0.6	243
13	Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review. <i>Journal of Clinical Oncology</i> , 2009, 27, 1906-1914.	0.8	242
14	Glofitamab, a Novel, Bivalent CD20-Targeting T-Cellâ€“Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1959-1970.	0.8	228
15	The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. <i>Haematologica</i> , 2014, 99, 1107-1113.	1.7	225
16	Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. <i>Haematologica</i> , 2006, 91, 482-9.	1.7	198
17	PET/CT for Therapy Response Assessment in Lymphoma. <i>Journal of Nuclear Medicine</i> , 2009, 50, 21S-30S.	2.8	193
18	Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. <i>Lancet</i> , The, 2021, 398, 1157-1169.	6.3	159

#	ARTICLE	IF	CITATIONS
19	Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. <i>Blood</i> , 2018, 131, 1456-1463.	0.6	130
20	Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e109-e116.	2.2	117
21	Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. <i>European Journal of Haematology</i> , 2007, 78, 206-212.	1.1	111
22	Treatment of Hodgkin lymphoma: the past, present, and future. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 543-556.	4.3	105
23	Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin Lymphoma. <i>New England Journal of Medicine</i> , 2022, 387, 310-320.	13.9	98
24	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018, 93, 57-68.	1.3	90
25	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , 2020, 135, 735-742.	0.6	86
26	In Vivo Treatment Sensitivity Testing With Positron Emission Tomography/Computed Tomography After One Cycle of Chemotherapy for Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 2705-2711.	0.8	83
27	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e410-e421.	2.2	83
28	Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. <i>Hematological Oncology</i> , 2006, 24, 146-150.	0.8	81
29	Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3993-3998.	0.8	74
30	Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. <i>Annals of Oncology</i> , 2017, 28, 1352-1358.	0.6	74
31	Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. <i>Haematologica</i> , 2012, 97, 931-936.	1.7	73
32	Outcome prediction by extranodal involvement, IPI, R <sub>1</sub> -IPI, and NCCN-IPI in the PET/CT and rituximab era: A Canadian study of 443 patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 1041-1046.	2.0	71
33	The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. <i>European Journal of Cancer</i> , 2017, 75, 195-203.	1.3	65
34	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , 2018, 29, 544-562.	0.6	64
35	Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. <i>Haematologica</i> , 2021, 106, 1129-1137.	1.7	57
36	FDG-PET in the clinical management of Hodgkin lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 52, 19-32.	2.0	55

#	ARTICLE	IF	CITATIONS
37	Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients. <i>American Journal of Hematology</i> , 2015, 90, 975-980.	2.0	51
38	Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 575-580.	2.0	49
39	PET/CT for Staging; Past, Present, and Future. <i>Seminars in Nuclear Medicine</i> , 2018, 48, 4-16.	2.5	48
40	Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients. <i>Journal of Nuclear Medicine</i> , 2018, 59, 589-595.	2.8	48
41	Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data. <i>Blood</i> , 2020, 136, 45-46.	0.6	45
42	The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study. <i>Annals of Oncology</i> , 2016, 27, 1095-1099.	0.6	43
43	PET/CT in the management of haematological malignancies. <i>European Journal of Haematology</i> , 2008, 80, 369-380.	1.1	41
44	Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. <i>Blood Advances</i> , 2021, 5, 2375-2384.	2.5	40
45	Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL). <i>Blood</i> , 2018, 132, 391-391.	0.6	40
46	Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 46-48.	0.6	38
47	Convolutional Neural Networks for Automated PET/CT Detection of Diseased Lymph Node Burden in Patients with Lymphoma. <i>Radiology: Artificial Intelligence</i> , 2020, 2, e200016.	3.0	37
48	Early interim PET scan in Hodgkin lymphoma: Where do we stand?. <i>Leukemia and Lymphoma</i> , 2008, 49, 659-662.	0.6	34
49	Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement. <i>British Journal of Haematology</i> , 2016, 175, 876-883.	1.2	34
50	Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. <i>Cancer Medicine</i> , 2020, 9, 6565-6575.	1.3	29
51	<sup>18</sup> F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. <i>Leukemia and Lymphoma</i> , 2015, 56, 2005-2012.	0.6	28
52	No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study. <i>British Journal of Haematology</i> , 2016, 173, 236-244.	1.2	28
53	A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait. <i>British Journal of Haematology</i> , 2015, 169, 435-444.	1.2	27
54	Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study. <i>Haematologica</i> , 2019, 104, e151-e153.	1.7	27

#	ARTICLE	IF	CITATIONS
55	CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial. <i>Blood</i> , 2018, 132, 226-226.	0.6	24
56	Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial. <i>Blood</i> , 2019, 134, 1584-1584.	0.6	24
57	Impact of <sup>18</sup> F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement. <i>Leukemia and Lymphoma</i> , 2014, 55, 2349-2355.	0.6	23
58	Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up. <i>British Journal of Haematology</i> , 2017, 176, 65-75.	1.2	23
59	CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 2871-2871.	0.6	20
60	Epcoritamab (GEN3013; DuoBody-CD3 $\alpha$ -CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8009-8009.	0.8	20
61	Clinical presentation and staging of Hodgkin lymphoma. <i>Seminars in Hematology</i> , 2016, 53, 148-154.	1.8	19
62	Comparison of 11 automated PET segmentation methods in lymphoma. <i>Physics in Medicine and Biology</i> , 2020, 65, 235019.	1.6	19
63	How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 322-327.	0.9	19
64	Interim Analysis of the Randomized Eortc/Lysa/Fil Intergroup H10 Trial On Early PET-Scan Driven Treatment Adaptation in Stage I/II Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 549-549.	0.6	19
65	Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3. <i>HemaSphere</i> , 2021, 5, e510.	1.2	18
66	Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRAVE study. <i>Blood</i> , 2018, 132, 2923-2923.	0.6	18
67	Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2021, 138, 525-525.	0.6	18
68	FDG-PET/CT based response-adapted treatment. <i>Cancer Imaging</i> , 2012, 12, 324-335.	1.2	17
69	ESMO Consensus Conference on malignant lymphoma: management of "ultra-high-risk" patients. <i>Annals of Oncology</i> , 2018, 29, 1687-1700.	0.6	17
70	Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 4762-4770.	2.5	17
71	First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody $\alpha$ -CD3 $\alpha$ -CD20) in B-Cell Non-Hodgkin Lymphomas. <i>Blood</i> , 2019, 134, 758-758.	0.6	17
72	Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 1698-1707.	1.4	15

#	ARTICLE	IF	CITATIONS
73	How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?. Hematology American Society of Hematology Education Program, 2012, 2012, 322-7.	0.9	14
74	Triangle: Autologous Transplantation after a Rituximab/Ibrutinib/ara-c Containing Induction in Generalized Mantle Cell Lymphoma - a Randomized European MCL Network Trial. Blood, 2019, 134, 2816-2816.	0.6	14
75	Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients. Cancer Medicine, 2020, 9, 4395-4404.	1.3	13
76	Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL). Blood, 2021, 138, 128-128.	0.6	13
77	Imaging of Non-Hodgkin Lymphomas: Diagnosis and Response-Adapted Strategies. Cancer Treatment and Research, 2015, 165, 125-146.	0.2	12
78	<sup>123</sup> I-MIBG imaging for detection of anthracycline-induced cardiomyopathy. Clinical Physiology and Functional Imaging, 2018, 38, 176-185.	0.5	12
79	Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. Hematological Oncology, 2021, 39, 185-195.	0.8	12
80	Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial. Blood, 2016, 128, 148-148.	0.6	12
81	Interobserver delineation uncertainty in involved-node radiation therapy (INRT) for early-stage Hodgkin lymphoma: on behalf of the Radiotherapy Committee of the EORTC lymphoma group. Acta Oncologica, 2017, 56, 608-613.	0.8	11
82	Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.. Journal of Clinical Oncology, 2021, 39, 7518-7518.	0.8	11
83	PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup. Blood, 2017, 130, 736-736.	0.6	11
84	Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study. Journal of Clinical Oncology, 2021, 39, 3463-3472.	0.8	10
85	B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG). Blood, 2018, 132, 926-926.	0.6	10
86	Suspected Richter transformation: positron emission tomography/computed tomography tells us who should have a biopsy and where. Leukemia and Lymphoma, 2014, 55, 233-234.	0.6	9
87	FDG-PET Response-adapted Therapy. Hematology/Oncology Clinics of North America, 2014, 28, 87-103.	0.9	9
88	First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1.. Journal of Clinical Oncology, 2022, 40, 7503-7503.	0.8	9
89	Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2014, 55, 1563-1569.	0.6	7
90	Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography. Oncologist, 2015, 20, 890-895.	1.9	7

#	ARTICLE	IF	CITATIONS
91	Little value of surveillance magnetic resonance imaging for primary <sc>CNS</sc> lymphomas in first remission: results from a Danish Multicentre Study. British Journal of Haematology, 2017, 176, 671-673.	1.2	7
92	Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study. Blood, 2021, 138, 2479-2479.	0.6	7
93	Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible. Blood, 2020, 136, 15-15.	0.6	7
94	Renal <sup>131</sup> I-hippuran extraction in man: effects of dopamine. British Journal of Clinical Pharmacology, 2002, 54, 675-677.	1.1	6
95	Pre-transplant positron emission tomography/computed tomography (PET/CT) in relapsed Hodgkin lymphoma: time to shift gears for PET-positive patients?. Leukemia and Lymphoma, 2011, 52, 1615-1616.	0.6	6
96	Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma. PET Clinics, 2014, 9, 443-455.	1.5	6
97	Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts). Blood, 2021, 138, 2478-2478.	0.6	6
98	Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial. Blood, 2021, 138, 2627-2627.	0.6	6
99	Improvements in Imaging of Hodgkin Lymphoma. Cancer Journal (Sudbury, Mass ), 2018, 24, 215-222.	1.0	5
100	<sup>123</sup> I-MIBG for detection of subacute doxorubicin-induced cardiotoxicity in patients with malignant lymphoma. Journal of Nuclear Cardiology, 2020, 27, 931-939.	1.4	5
101	Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial. Blood, 2020, 136, 36-36.	0.6	5
102	Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. Blood, 2020, 136, 26-28.	0.6	5
103	The Complementary Prognostic Role of Baseline and Interim PET in Predicting Treatment Outcome in Advanced-Stage Hodgkin Lymphoma. Blood, 2014, 124, 4405-4405.	0.6	5
104	Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).. Journal of Clinical Oncology, 2018, 36, 7539-7539.	0.8	5
105	Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study. Blood, 2018, 132, 2904-2904.	0.6	4
106	The Optimal Timing of Interim <sup>18</sup> F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium. Blood, 2019, 134, 487-487.	0.6	4
107	Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Lymphoma. Blood, 2020, 136, 16-17.	0.6	4
108	Risk Factors and a Prognostic Score for Progression Free Survival after Treatment with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin Lymphoma (rrHL). Blood, 2015, 126, 1978-1978.	0.6	4

#	ARTICLE	IF	CITATIONS
109	The prognostic value of interim positron emission tomography scans combined with immunohistochemical data in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2005, 90, 1711-3.	1.7	4
110	Volume of Abnormal Tumour Tissue on FDG-PET - a Predictor of Progression-Free Survival in Hodgkin Lymphoma?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, S45.	0.4	3
111	PET imaging in lymphoma. <i>Expert Review of Hematology</i> , 2009, 2, 261-276.	1.0	3
112	Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1221-1223.	0.8	3
113	PET-adapted treatment of Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 1200-1201.	0.6	3
114	Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk. <i>BMC Cancer</i> , 2020, 20, 1202.	1.1	3
115	Interim FDG PET/CT to predict progression-free survival (PFS) better than clinical and baseline metabolic measurements in Hodgkin lymphoma (cHL).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8555-8555.	0.8	3
116	Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7575-TPS7575.	0.8	3
117	Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose / Positron Emission Tomography in advanced Hodgkin lymphoma. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, , .	0.4	3
118	Axillary lymph nodes on PET in Hodgkin lymphoma after COVID-19 vaccination. <i>EJHaem</i> , 2021, 2, 885-886.	0.4	3
119	Cancer mortality does not differ between migrants and Danish-born patients. <i>Danish Medical Journal</i> , 2014, 61, A4848.	0.5	3
120	Uptake of FDG in Lemierre's syndrome with normal leucocyte scintigraphy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 489-489.	3.3	2
121	Routine follow-up scanning of patients with lymphoma: who, when, how, and why?. <i>Leukemia and Lymphoma</i> , 2011, 52, 552-553.	0.6	2
122	When and how to perform surveillance imaging in patients with lymphoma, and is it worth it?. <i>Leukemia and Lymphoma</i> , 2012, 53, 1015-1016.	0.6	2
123	The role of bone marrow biopsy in Hodgkin lymphoma staging: "To be, or not to be, that is the question". <i>Leukemia and Lymphoma</i> , 2012, 53, 523-524.	0.6	2
124	Targeted immunotherapy in Hodgkin lymphoma. <i>Blood</i> , 2015, 125, 3967-3968.	0.6	2
125	FDG-PET for the early treatment monitoring, for final response and follow-up evaluation in lymphoma. <i>Clinical and Translational Imaging</i> , 2015, 3, 271-281.	1.1	2
126	New clues to the prognostic challenge of Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 277-278.	0.6	2

#	ARTICLE	IF	CITATIONS
127	Functional Imaging in Hodgkin Lymphoma. Hematologic Malignancies, 2015, , 107-130.	0.2	2
128	Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. Blood, 2020, 136, 16-18.	0.6	2
129	Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial. Blood, 2016, 128, 184-184.	0.6	2
130	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 1874-1874.	0.6	2
131	Correlation of FDG-PET results after one cycle and after two cycles of chemotherapy in Hodgkin lymphoma.. Journal of Clinical Oncology, 2010, 28, 8061-8061.	0.8	2
132	The Role of Imaging in Radiotherapy for Hodgkin Lymphoma. , 2011, , 81-89.		1
133	Reply to G. Keramida et al. Journal of Clinical Oncology, 2015, 33, 4121-4122.	0.8	1
134	Advances in the diagnosis and treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Cancer Treatment Communications, 2015, 4, S1-S11.	0.4	1
135	A small change makes a big difference in Hodgkin lymphoma. Blood, 2018, 132, 2214-2215.	0.6	1
136	Reference values for the EORTC QLQâ€“30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors. European Journal of Haematology, 2021, 106, 697-707.	1.1	1
137	Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts).. Journal of Clinical Oncology, 2021, 39, 7519-7519.	0.8	1
138	Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma. Cancer Reports, 2021, , e1524.	0.6	1
139	The Absolute Number of Extranodal Sites Detected By PET-CT Is a Powerful Predictor of Secondary Central Nervous System Involvement in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. Blood, 2015, 126, 3905-3905.	0.6	1
140	Antibodyâ€“Drug Conjugates in Relapsed/Refractory CD30-positive Lymphomas. European Oncology and Haematology, 2015, 11, 123.	0.0	1
141	Different Histopathological Subtypes of Hodgkin Lymphoma Have Significantly Different Levels of FDG Uptake.. Blood, 2005, 106, 969-969.	0.6	1
142	Routine Bone Marrow Biopsy Adds Little Diagnostic Information in Patients with Newly Diagnosed Hodgkin Lymphoma Undergoing PET/CT Staging. Blood, 2011, 118, 2627-2627.	0.6	1
143	Role of Bone Marrow Biopsy in the Staging of Diffuse Large B-Cell Lymphoma in the PET/CT Era. Blood, 2014, 124, 2960-2960.	0.6	1
144	Prognostic Impact of Extranodal Diffuse Large B-Cell Lymphoma in the Era of Immunochemotherapy and PET/CT Staging. Blood, 2014, 124, 1630-1630.	0.6	1

#	ARTICLE	IF	CITATIONS
145	55 INVITED FDG-PET in Hodgkin Lymphoma. European Journal of Cancer, 2011, 47, S16.	1.3	0
146	236 INVITED Molecular Imaging for Personalised Treatment of Malignant Lymphoma. European Journal of Cancer, 2011, 47, S56.	1.3	0
147	Pet-Based Decisions in Hodgkin Lymphoma. Annals of Oncology, 2014, 25, iv45.	0.6	0
148	Interobserver Delineation Uncertainty in Involved Node Therapy for Early-Stage Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2016, 96, E490-E491.	0.4	0
149	Reply to H.J adams et al: "œls FDG-PET/CT a sensitive and specific method for the detection of extranodal involvement in diffuse large B-cell lymphoma?" American Journal of Hematology, 2016, 91, E2-E3.	2.0	0
150	Can we improve on ibrutinib in mantle cell lymphoma?. Lancet Haematology,the, 2018, 5, e98-e99.	2.2	0
151	O17-1 Subcutaneous (SC) epcoritamab induces complete responses across R/R B-cell NHL subtypes: Updated dose-escalation data. Annals of Oncology, 2021, 32, S292.	0.6	0
152	HL-147: Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S371.	0.2	0
153	Poster:ABCL-360 Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S243.	0.2	0
154	Functional Imaging. , 2011, , 77-95.		0
155	Clinical Features and Outcome in Newly Diagnosed Hodgkin Lymphoma Patients Presenting with PET/CT-Ascertained Focal Skeletal Lesions.. Blood, 2012, 120, 2637-2637.	0.6	0
156	Disease Extent in Newly Diagnosed Hodgkin Lymphoma: A Comparison of CT and PET/CT Staged Patients. Blood, 2012, 120, 1532-1532.	0.6	0
157	The International Prognostic Index Predicts Outcome In Patients With Untreated Nodal Peripheral T-Cell Lymphomas Staged With PET/CT. Blood, 2013, 122, 5077-5077.	0.6	0
158	PET/CT for HL Staging. , 2016, , 1-13.		0
159	Fertility Rates in Young Hodgkin Lymphoma Survivors: A Danish Nationwide Cohort Study of 769 Patients. Blood, 2019, 134, 2841-2841.	0.6	0
160	Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study. Blood, 2019, 134, 4026-4026.	0.6	0
161	Functional Imaging in Hodgkin Lymphoma. Hematologic Malignancies, 2020, , 113-143.	0.2	0